French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with an equity value of $2.9 billion. The deal will allow Sanofi to add to its portfolio, TZIELD, which was approved in the U.S. last year as the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D). Provention announced late last year a deal with Sanofi to co-promote the treatment in the U.S..
Source: finance.yahoo.com
Related posts:
I’m 56 and plan to retire at 62. I’ll have both a state retirement plan and Social Security — but I ...
How Much Cash Can I Withdraw From My Bank?
An Oil Company Went Up in Flames, Burning Lenders and the Planet
More boomers are staying in their jobs instead of retiring. They’re working longer hours and making ...
Exxon, Chevron, and 3 Other Dividend Aristocrat Stocks With Secure Payouts